Drug Profile

CX 2051

Alternative Names: CX-2051; EpCAM PROBODY^® ADC

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmunoGen
Developer CytomX Therapeutics
Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

12 May 2025 Efficacy and adverse event data from phase I trial in Solid tumours released by CytomX Therapeutics
12 May 2025 CytomX Therapeutics plans a phase Ib trial for Solid tumors in 2026
12 May 2025 CytomX Therapeutics plans a phase II trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in 1H 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com